{"id":"W4402364275","doi":"10.1007/s12325-024-02974-y","title":"Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)","year":2024,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Eli Lilly and Company","keywords":"Medicine; Atopic dermatitis; Placebo; Rheumatology; Dermatology; Internal medicine; Randomized controlled trial; Physical therapy; Double blind; Alternative medicine; Pathology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001014772,0.000326055,0.001783109,0.0002661391,0.00005992862,0.00005371151,0.0001012759,0.00007869246,0.00005162854],"category_scores_gemma":[0.0001711977,0.0001900017,0.00023317,0.0003096507,0.0004126586,0.0005825401,0.00002235768,0.0002132598,0.000003065852],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004732604,"about_ca_system_score_gemma":0.0002026799,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001141727,"about_ca_topic_score_gemma":0.0002054025,"domain_scores_codex":[0.9974767,0.0004100027,0.001057436,0.0004506128,0.0002446293,0.0003606001],"domain_scores_gemma":[0.9975323,0.001658774,0.0002263696,0.0003498829,0.00006345289,0.0001692179],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9485218,0.0009091563,0.007251374,0.0002315803,0.000532969,0.0003894971,0.001187195,0.0002163464,0.0003251638,0.0004910766,0.00004855475,0.0398953],"study_design_scores_gemma":[0.989685,0.0003519021,0.0006609893,0.0007483178,0.0002078798,0.00003330334,0.0002580018,0.001335378,0.002548663,0.002353166,0.001568133,0.0002492742],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8753749,0.1188202,0.0004196971,0.0007626044,0.0001985974,0.004278647,0.00003347437,0.00005964677,0.00005222339],"genre_scores_gemma":[0.9502738,0.04714492,0.0002417467,0.0006417538,0.0000477328,0.001463555,0.00003897623,0.00003572351,0.0001117734],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07489894,"threshold_uncertainty_score":0.7748043,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03107844180460009,"score_gpt":0.3778267599319135,"score_spread":0.3467483181273134,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}